Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis

Key Takeaways

• Patients achieving HBsAg loss with elebsiran plus pegylated interferon showed durable immunological control with minimal rebound
• Most HBsAg rebounds remained below 10 IU/mL with infrequent HBV DNA rebound and no significant liver enzyme elevation
• Results support potential for safe discontinuation of nucleoside reverse transcriptase inhibitors in combination regimens

---

Brii Bio Reports Promising Long-Term Hepatitis B Control Data

Brii Biosciences presented encouraging cross-study analysis results at the Asia-Pacific Association for the Study of the Liver (APASL) 2026 conference, demonstrating sustained hepatitis B surface antigen (HBsAg) loss in patients treated with combination therapy including their investigational drug elebsiran.

Treatment Outcomes Show Durable Control

The analysis examined participants who achieved HBsAg loss following treatment with pegylated interferon alfa (PEG-IFNα) combined with either elebsiran or BRII-179. Post-treatment monitoring revealed favorable clinical outcomes, with the majority of patients maintaining low HBsAg levels even after treatment discontinuation.

Crucially, when HBsAg rebound occurred, levels typically remained below 10 IU/mL, indicating maintained immunological control. Additionally, HBV DNA rebound was infrequent and notably did not correlate with clinically significant alanine aminotransferase (ALT) elevation, suggesting preserved liver function.

Implications for Treatment Strategy

These findings carry significant implications for hepatitis B treatment paradigms. The data suggest that patients achieving functional cure through combination therapy may safely discontinue nucleos(t)ide reverse transcriptase inhibitors (NRTIs), potentially reducing long-term treatment burden and associated costs.

The durable post-treatment immunological control observed supports the hypothesis that combining pegylated interferon with novel agents like elebsiran may reset immune responses against hepatitis B virus more effectively than traditional monotherapy approaches.

Market and Clinical Impact

For the estimated 296 million people living with chronic hepatitis B globally, these results represent progress toward achieving functional cure - defined as sustained HBsAg loss. Current standard-of-care NRTIs require lifelong administration, making safe treatment discontinuation a critical unmet medical need.

Brii Bio’s approach addresses this gap by potentially enabling finite treatment duration while maintaining viral suppression. The company continues advancing its hepatitis B pipeline, with elebsiran representing a key component of their combination therapy strategy targeting functional cure rather than mere viral suppression.

---

Frequently Asked Questions

What does HBsAg loss mean for hepatitis B patients?

HBsAg loss indicates functional cure, where the virus becomes undetectable and patients may safely stop antiviral treatment while maintaining protection against disease progression.

When will elebsiran combination therapy be available to patients?

Elebsiran remains in clinical development. Brii Bio has not announced specific timelines for regulatory submission, though these positive results support continued advancement through clinical trials.

How does this compare to current hepatitis B treatments?

Current treatments like nucleoside analogs require lifelong use and rarely achieve functional cure. This combination approach potentially offers finite treatment duration with sustained viral control after discontinuation.

Related coverage

• KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
• EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors
• Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains